Vagus nerve stimulation may be considered medically necessary as a treatment of medically refractory seizures.

Vagus nerve stimulation is considered investigational as a treatment of other conditions, including but not limited to:
- Depression
- Essential tremor
- Fibromyalgia
- Headaches
- Heart failure
- Obesity
- Tinnitus
- Traumatic brain injury
- Upper-limb impairment due to stroke

Transcutaneous (nonimplantable) vagus nerve stimulation devices are considered investigational for all indications.

Medically refractory seizures are defined as seizures that occur despite therapeutic levels of antiepileptic drugs or seizures that cannot be treated with therapeutic levels of antiepileptic drugs because of intolerable adverse events of these drugs.

Vagus nerve stimulation has been evaluated for the treatment of obesity. This indication is addressed in Blue Shield of California Medical Policy: Vagus Nerve Blocking Therapy for Treatment of Obesity.

Coding
Vagus nerve stimulation requires not only the surgical implantation of the device but also subsequent neurostimulator programming, which occurs intraoperatively and typically during additional outpatient visits. There are CPT codes that specifically describe the neurostimulator programming and analysis of cranial nerve stimulation (i.e., vagus nerve) as follows:

- **95974**: Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude, pulse duration, configuration of waveform, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour
- **95975**: Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude, pulse duration, configuration of waveform, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)

Description
Stimulation of the vagus nerve can be performed using a pulsed electrical stimulator implanted within the carotid artery sheath. This technique has been proposed as a treatment for refractory
seizures, depression, and other disorders. There are also devices available that are implanted at different areas of the vagus nerve. This evidence review also addresses devices that stimulate the vagus nerve transcutaneously.

### Related Policies

- Vagus Nerve Blocking Therapy for Treatment of Obesity

### Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates [e.g., Federal Employee Program (FEP)] prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

### Regulatory Status

In 1997, the NeuroCybernetic Prosthesis (NCP®) System (Cyberonics), a VNS device, was approved by the FDA through the premarket approval process for use in conjunction with drugs or surgery “...as an adjunctive treatment of adults and adolescents over 12 years of age with medically refractory partial onset seizures.”¹ There have been subsequent expanded approvals. FDA product code: LYF.

In May 2015, a related VNS therapy, AspireSR® (LivaNova), received supplemental premarketing approval from the FDA, although the device was recalled in August 2017.² The AspireSR® device detects high heart rates associated with seizures and responds with stimulation. Adjunctive use of the AspireSR® for the treatment of epileptic seizures was indicated for patients over 4 years of age who suffer from partial-onset seizures that do not respond to antiepileptic medication.

In May 2017, the gammaCore-S® (electroCore), a noninvasive VNS device, was cleared for marketing by the FDA through the 510(k) process (K171306) for the acute treatment of adults with episodic cluster headaches.³ When the device is applied to the side of the neck by the patient, mild electrical stimulation of the vagus nerve is carried to the central nervous system. Each stimulation using gammaCore-S® lasts 2 minutes. The patient controls the stimulation strength. FDA product code: PKR.

Cerbomed (Erlangen, Germany) has developed a transcutaneous VNS (t-VNS®) system that uses a combined stimulation unit and ear electrode to stimulate the auricular branch of the vagus nerve, which supplies the skin over the concha of the ear. Patients self-administer electrical stimulation for several hours a day; no surgical procedure is required. The device received the CE mark in Europe in 2011 but has not been FDA-approved for use in the United States.

Table 1 includes updates on stimulators pertinent to this evidence review.

### Table 1. FDA-Approved or -Cleared Vagus Nerve Stimulators

<table>
<thead>
<tr>
<th>Device Name</th>
<th>Manufacturer</th>
<th>Cleared</th>
<th>PMA/510(k)</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeuroCybernetic Prosthesis (NCP®)</td>
<td>Cyberonics</td>
<td>1997</td>
<td>P970003</td>
<td>Indicated or adjunctive treatment of adults and adolescents &gt;12 y of age with medically refractory partial-onset seizures</td>
</tr>
</tbody>
</table>
Vagus Nerve Stimulation

<table>
<thead>
<tr>
<th>Device Name</th>
<th>Manufacturer</th>
<th>Cleared</th>
<th>PMA/510(k)</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2005</td>
<td>P970003/S50</td>
<td>Expanded indication for adjunctive long-term treatment of chronic or recurrent depression for patients ≥18 y of age experiencing a major depressive episode and have not had an adequate response to ≥4 adequate antidepressant treatments</td>
</tr>
<tr>
<td>gammaCore®</td>
<td>ElectroCore</td>
<td>2017</td>
<td>K171306</td>
<td>Indicated for acute treatment of pain associated with episodic cluster headache in adults using noninvasive VNS on the side of the neck</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2017</td>
<td>P970003/S207</td>
<td>Expanded indicated use as adjunctive therapy for seizures in patients ≥4 y of age with partial-onset seizures that are refractory to antiepileptic medications</td>
</tr>
</tbody>
</table>

FDA: Food and Drug Administration; PMA: premarket approval; VNS: vagus nerve stimulation.

Rationale

Background

Vagus Nerve Stimulation

Vagus nerve stimulation (VNS) was initially investigated as a treatment alternative in patients with medically refractory partial-onset seizures for whom surgery is not recommended or for whom surgery has failed. Over time, the use of VNS has expanded to include generalized seizures, and it has been investigated for a range of other conditions.

While the mechanisms for the therapeutic effects of VNS are not fully understood, the basic premise of VNS in the treatment of various conditions is that vagal visceral afferents have a diffuse central nervous system projection, and activation of these pathways has a widespread effect on neuronal excitability. An electrical stimulus is applied to axons of the vagus nerve, which have their cell bodies in the nodose and junctional ganglia and synapse on the nucleus of the solitary tract in the brainstem. From the solitary tract nucleus, vagal afferent pathways project to multiple areas of the brain. VNS may also stimulate vagal efferent pathways that innervate the heart, vocal cords, and other laryngeal and pharyngeal muscles, and provide parasympathetic innervation to the gastrointestinal tract.

A type of VNS device addressed in this evidence review consists of an implantable, programmable electronic pulse generator that delivers stimulation to the left vagus nerve at the carotid sheath. The pulse generator is connected to the vagus nerve via a bipolar electrical lead. Surgery for implantation of a vagal nerve stimulator involves implantation of the pulse generator in the infraclavicular region and wrapping 2 spiral electrodes around the left vagus nerve within the carotid sheath. The programmable stimulator may be programmed in advance to stimulate at regular intervals or on demand by patients or family by placing a magnet against the subclavicular implant site.

Various types of devices that transcutaneously stimulate the vagus nerve have been developed as well. The U.S. Food and Drug Administration (FDA) has not approved any transcutaneous VNS devices.

Other types of implantable vagus nerve stimulators that are placed in contact with the trunks of the vagus nerve at the gastroesophageal junction are not addressed in this evidence review.

Indications

VNS was originally approved for the treatment of medically refractory epilepsy. Significant advances have been made since then in the surgical and medical treatment of epilepsy, and newer, more recently approved medications are available. Despite these advances, however, 25% to 50% of patients with epilepsy experience breakthrough seizures or suffer from debilitating
adverse events of antiepileptic drugs. For these patients, VNS therapy has been used as an alternative or adjunct to epilepsy surgery or medications.

Based on observations that patients treated with VNS experience improvements in mood, VNS has been evaluated for the treatment of refractory depression. VNS has been investigated for multiple other conditions which may be affected by either the afferent or efferent stimulation of the vagus nerve, including heart failure, headaches, tremor, fibromyalgia, tinnitus, and traumatic brain injury.

**Literature Review**
Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice. The following is a summary of the key literature to date.

**Vagus Nerve Stimulation**
**Clinical Context and Test Purpose**
The purpose of implantable vagus nerve stimulation (VNS) is to apply pulsed electrical energy via the vagus nerve to alter aberrant neural activity resulting in seizures.

The question addressed in this evidence review is this: Does the use of VNS as a treatment for medically refractory seizures result in changes in management and improvement in health outcomes?

The following PICOTS were used to select literature to inform this review.

**Patients**  
The relevant population of interest is patients with medically refractory seizures.

**Interventions**  
The test being considered is implantable VNS.

**Comparators**  
The following practices are currently being used: conventional antiepileptic drugs and/or resective surgery.

**Outcomes**  
Outcomes of interest are clinical validity or diagnostic accuracy (test accuracy, test validity [e.g., sensitivity, specificity]), and clinical utility that includes consideration of avoidance of harms.
Timing
VNS is typically used when a patient has had unsuccessful medical therapy, been intolerant of medical therapy, or had failed resective surgery.

Setting
VNS is initiated with surgical implantation and subsequently administered in outpatient and home care settings.

Systematic Reviews
Reports on the use of VNS to treat medication-resistant seizure disorders date to the 1990s and were coincident with preapproval and early postapproval study of the device.

Treatment-Resistant Seizures
Vagus Nerve Stimulation for Adult Partial-Onset Seizures
Englot et al (2011) conducted a meta-analysis of the literature through November 2010 assessing the efficacy of VNS and its predictors of response. Table 2 summarizes the 15 RCTs and prospective observational studies selected. Overall, VNS predicted a 50% or greater reduction in seizure frequency at last follow-up, the main effect, with an odds ratio of 1.83 (95% confidence interval [CI], 1.80 to 1.86; p < 0.001).

Table 2. Summary of Trials and Studies Included in Meta-Analysis

<table>
<thead>
<tr>
<th>Study (Year)</th>
<th>N</th>
<th>Duration of FU</th>
<th>No. of Sites</th>
<th>Design</th>
<th>Seizure Type</th>
<th>Seizure Frequency Reduction &gt;50%, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben-Menachem et al (1994)⁵</td>
<td>114</td>
<td>3 mo</td>
<td>Multisite</td>
<td>Blinded RCT</td>
<td>Partial</td>
<td>31</td>
</tr>
<tr>
<td>Ben-Menachem et al (1999)¹⁰</td>
<td>64</td>
<td>3-64 mo</td>
<td>Single</td>
<td>Blinded RCT</td>
<td>Partial</td>
<td>57</td>
</tr>
<tr>
<td>Parker et al (1999)¹¹</td>
<td>15</td>
<td>1 y</td>
<td>Single</td>
<td>Prospective OBS</td>
<td>Mixed</td>
<td>27</td>
</tr>
<tr>
<td>Chavel et al (2003)¹⁴</td>
<td>29</td>
<td>1-2 y</td>
<td>Single</td>
<td>Prospective OBS</td>
<td>Partial</td>
<td>54b</td>
</tr>
<tr>
<td>Vonck et al (1999; 2004)¹⁵</td>
<td>118</td>
<td>&gt;6 mo</td>
<td>Multisite</td>
<td>Prospective OBS</td>
<td>Mixed</td>
<td>50</td>
</tr>
<tr>
<td>Majoie et al (2001; 2005)¹⁶</td>
<td>19</td>
<td>2 y</td>
<td>Single</td>
<td>Prospective OBS</td>
<td>Mixed</td>
<td>21</td>
</tr>
<tr>
<td>Huf et al (2005)¹⁷</td>
<td>49</td>
<td>2 y</td>
<td>Single</td>
<td>Prospective OBS</td>
<td>NR</td>
<td>28</td>
</tr>
<tr>
<td>Kang et al (2006)¹⁸</td>
<td>16</td>
<td>&gt;1 y</td>
<td>Multisite</td>
<td>Prospective OBS</td>
<td>Mixed</td>
<td>50</td>
</tr>
<tr>
<td>Ardesch et al (2007)²¹</td>
<td>19</td>
<td>&gt;2 y</td>
<td>Single</td>
<td>Prospective OBS</td>
<td>Partial</td>
<td>33e</td>
</tr>
</tbody>
</table>

Adapted from Englot et al (2011).⁴
FU: follow-up; NR: not reported; OBS: observational; RCT: randomized controlled trial.

This evidence review was informed, in part, by a 1998 Blue Cross Blue Shield Association Technology Evaluation Center (TEC) Assessment on the treatment of seizures that offered the following conclusions²²:

- For patients, 12 years of age and older with medically refractory partial-onset seizures, for whom surgery is not recommended or for whom surgery has failed evidence, is available from 2 multicenter, randomized, blinded, active control studies submitted for device registration.⁵,⁶ The trials, which were limited to patients with partial-onset seizures, and included outcomes for 314 patients, presented sufficient data to demonstrate that VNS is a beneficial adjunct to optimal antiepileptic drug therapy for the treatment of these seizures. In patients with at least 6 partial-onset seizures per month, VNS reduced seizure frequency by approximately 25% after 3 months of treatment. In patients who achieved an initial
reduction in seizure frequency, the beneficial treatment effect appeared to be maintained and may increase with time. The results of these studies are included in Table 2.

- Adverse events were mild and consisted primarily of hoarseness or voice change during “on” periods of stimulation.

Based on this TEC Assessment, earlier versions of this evidence review supported the use of VNS for partial-onset seizures for patients older than 12 years of age in individuals for whom surgery has not been recommended or for whom surgery has failed.

Panebianco et al (2015) updated a Cochrane systematic review and meta-analysis of VNS to treat partial seizures. Reviewers specifically evaluated randomized, double-blind, parallel or crossover, controlled trials of VNS as an add-on treatment comparing high- and low-stimulation paradigms plus VNS stimulation with no stimulation or a different intervention. Five trials (n=439 participants) compared high-frequency stimulation with low-frequency stimulation in participants ages 12 to 60 years, and another trial compared high-frequency stimulation with low-frequency stimulation in children. The overall relative risk for a response to high stimulation compared with low-stimulation using the fixed-effect model was calculated to be 1.73 (95% CI, 1.13 to 2.64; p=0.01), showing that patients receiving high stimulation were more likely to show a 50% or greater reduction in seizure frequency.

**Randomized Controlled Trials**

Ryvlin et al (2014) reported on an RCT on long-term quality of life outcomes for 112 patients with medication-resistant focal seizures, which supported the beneficial effects of VNS for this group.

**Vagus Nerve Stimulation for Adult Generalized Seizures**

Resective surgery is a less attractive therapeutic option for individuals with generalized treatment-resistant seizures that may be multifocal or involve an eloquent area. VNS has been evaluated as an alternative to disconnection procedures such as surgical division of the corpus callosum.

The evidence for the efficacy of VNS for generalized seizures in adults is primarily from observational data, including registries and small cohort studies.

Englot et al (2016) examined freedom from seizure rates and predictors across 5554 patients enrolled in the VNS Therapy Patient Outcomes Registry. The registry was established in 1999, after the 1997 U.S. Food and Drug Administration approval of VNS, and is maintained by the manufacturer of the device, Cyberonics. Data were prospectively collected by 1285 prescribing physicians from 978 centers (911 in the United States and Canada and 67 internationally) at patients’ preoperative baselines and various intervals during therapy. During active data collection, participation in the registry included approximately 18% of all implanted VNS devices. The database was queried in January 2015, and all seizure outcomes reported with the 0- to 4-, 4- to 12-, 12- to 24-, and 24- to 48-month time ranges after VNS device implantation were extracted and compared with patient preoperative baseline. Available information was tracked at each time point of data submission for the following outcomes: patient demographics, epilepsy etiology and syndrome, historical seizure types and frequencies, quality of life, physician global assessment, current antiepileptic drugs, medication changes, malfunctions, battery changes, and changes in therapy. At each observation point, responders were defined as having a 50% or greater decrease in seizure frequency compared with baseline and nonresponders as less than a 50% decrease. A localized epilepsy syndrome such as partial-onset seizures was recorded in 59% of the registry participants, generalized epilepsy in 27%, and 11% had a syndromic etiology (e.g., Lennox-Gastaut).

The outcomes for the approximately 1500 registry enrollees with generalized seizures are summarized in Table 3. These rates did not differ statistically from participants with predominantly partial seizures.
Table 3. Summary of VNS Registry Outcomes

<table>
<thead>
<tr>
<th>Duration</th>
<th>Responder Rate, %</th>
<th>Seizure Freedom Rate, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4 mo</td>
<td>50</td>
<td>7</td>
</tr>
<tr>
<td>4-12 mo</td>
<td>55</td>
<td>8</td>
</tr>
<tr>
<td>12-24 mo</td>
<td>55</td>
<td>8</td>
</tr>
<tr>
<td>24-48 mo</td>
<td>~60(^a)</td>
<td>~9(^a)</td>
</tr>
</tbody>
</table>

VNS: vagus nerve stimulation.

\(^a\) Responder rate: ≥50% decrease in seizure frequency.

\(^b\) Approximation based on publication Figure 1 and narrative.

Garcia-Navarrete et al (2013) evaluated outcomes after 18 months of follow-up for a prospective cohort of 43 patients with medication-resistant epilepsy who underwent VNS implantation.\(^29\) Subjects’ seizure types were heterogeneous, but 52% had generalized epilepsy. Pharmacotherapy was unchanged during the study. Twenty-seven (63%) subjects were described as “responders,” defined as having a 50% or greater reduction in seizure frequency compared with the year before VNS implantation. The difference in reduction of seizure frequency was not statistically significant between subjects with generalized and focal epilepsy.

### Vagus Nerve Stimulation for Pediatric Seizures

The evidence for VNS for pediatric seizures consists of a variety of small noncomparator trials, prospective observational studies, and retrospective case series. As in the adult studies, there is heterogeneity of seizure etiologies: mixed, syndromic, and idiopathic; there is also a generalized and limited information on concomitant antiepileptic drug requirement. Some studies have defined pediatric patients as less than 12 years of age and others have defined them as less than 18 years and may have included patients as young as 2 to 3 years of age. Study subpopulations may have had prior failed resective surgery. Complete freedom from seizures is the exception, and the primary reported end point is 50% or more reduction in seizure frequency, determined over varying lengths of follow-up. There is an overlap of authors for multiple studies suggesting utilization of VNS in specialized clinical care environments. Multiple studies have some form of innovator device company sponsorship.

Table 4 summarizes the evaluable literature on VNS in pediatric populations of all seizure types.

Table 4. Summary of Vagus Nerve Stimulation Pediatric Studies

<table>
<thead>
<tr>
<th>Author (Year)</th>
<th>Study Type</th>
<th>Sample</th>
<th>Seizure Disorder Type</th>
<th>Duration of FU</th>
<th>SFR ≥50% or Median Reduction, n (%)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Murphy et al (1999)(^31)</td>
<td>Prospective OBS</td>
<td>60</td>
<td>Mixed</td>
<td>18 mo</td>
<td>46 (42)(^a)</td>
<td>Age: 26% &lt;12 y</td>
</tr>
<tr>
<td>Patwardhan et al (2000)(^32)</td>
<td>Case series</td>
<td>38</td>
<td>Mixed</td>
<td>12 mo (median)</td>
<td>26 (68)</td>
<td>Age: 11 mo to 16 y</td>
</tr>
<tr>
<td>Frost et al (2001)(^33)</td>
<td>Retrospective case review</td>
<td>50</td>
<td>LGS</td>
<td>6 mo</td>
<td>50 (57.9)(^a)</td>
<td>Age: 13 y (median)</td>
</tr>
<tr>
<td>You et al (2007)(^34)</td>
<td>Prospective OBS</td>
<td>28</td>
<td>Mixed</td>
<td>31.4 mo (mean)</td>
<td>15 (53.6)</td>
<td>Age range: 2-17 y</td>
</tr>
<tr>
<td>Klinkenberg et al (2012)(^24)</td>
<td>RCT(^b)</td>
<td>41</td>
<td>Mixed</td>
<td>19 wk</td>
<td>High-stim: 3/21 (14.2) Low-stim: 4/20 (20)</td>
<td>Age range: 3-17 y</td>
</tr>
<tr>
<td>Cukiert et al (2013)(^35)</td>
<td>Case series</td>
<td>24</td>
<td>LGS</td>
<td>24 mo</td>
<td>NR(^c)</td>
<td>Age: &lt;12 y</td>
</tr>
<tr>
<td>Healy et al (2013)(^36)</td>
<td>Retrospective case review</td>
<td>16</td>
<td>Unknown</td>
<td>3-y review</td>
<td>9 (56)</td>
<td>Age: &lt;12 y</td>
</tr>
<tr>
<td>Terra et al (2014)(^37)</td>
<td>Retrospective case-control(^d)</td>
<td>36</td>
<td>Mixed</td>
<td>3-y review</td>
<td>VNS group: 20 (55.4)</td>
<td>Age: &lt;18 y Difference from baseline seizure frequency(^e)</td>
</tr>
</tbody>
</table>
Section Summary: Treatment-Resistant Seizures

The evidence on the efficacy of VNS for treatment of medically refractory seizures consists of 2 RCTs reported at the time of initial U.S. Food and Drug Administration approval of the marketed device, two recent meta-analysis, and numerous uncontrolled studies. The RCTs both reported a significant reduction in seizure frequency with VNS for patients with partial-onset seizures. The uncontrolled studies and case series have consistently reported reductions of clinical significance, defined as a 50% or more reduction in seizure frequency in both adults and children over almost 2 decades of publications. Interpretation of all outcomes and results were limited by the variety of comparators (when used), variability in length of follow-up, limited published data on antiepileptic medication requirements, mixed seizure etiologies, and history of prior failed resective surgery. There is an overlap of authors across multiple studies, suggesting utilization of VNS in specialized clinical care environments. Multiple studies have some form of innovator device company sponsorship.

Treatment-Resistant Depression

Interest in the application of VNS for treatment of treatment-resistant depression is related to reports of improvement in depressed mood among epileptic patients undergoing VNS.39 TEC Assessments written in 2005 and updated in 2006 concluded that evidence was insufficient to permit conclusions about the effect of VNS therapy on depression.40,41 The available evidence for these TEC Assessments included study groups assembled by the manufacturer of the device (Cyberonics) and have since been reported on in various publications.42,43 Analyses from these study groups were presented for Food and Drug Administration review, and consisted of a case series of 60 patients receiving VNS (study D-01), a short-term (i.e., 3-month) sham-controlled randomized trial of 221 patients (study D-02), and an observational study comparing 205 patients on VNS therapy with 124 patients receiving ongoing treatment for depression (study D-04).44 Patients who responded to sham treatment in the short-term RCT (~10%) were excluded from the long-term observational study.

The primary outcome evaluated was the relief of depression symptoms that can usually be assessed by any one of many different depression symptom rating scales. A 50% reduction from baseline score is considered to be a reasonable measure of treatment response. Improvement in depression symptoms may allow reduction of pharmacologic therapy for depression, with a reduction in adverse events related to that form of treatment. In the studies evaluating VNS therapy, the four most common instruments used were the Hamilton Rating Scale for Depression, Clinical Global Impression, Montgomery and Asberg Depression Rating Scale, and the Inventory of Depressive Symptomatology (IDS).

Several case series published before the randomized trial showed rates of improvement with VNS, as measured by a 50% improvement in depression score, of 31% at 10 weeks to greater than 40% at 1 to 2 years, but there were some losses to follow-up.45-47 Natural history, placebo effects, and patient and provider expectations make it difficult to infer efficacy from case series data.
The randomized study (D-02) that compared VNS therapy with a sham control (implanted but inactivated VNS) showed a nonstatistically significant result for the principal outcome.\textsuperscript{43,44} Fifteen percent of VNS subjects responded vs 10% of control subjects (p=0.31). The Inventory for Depressive Symptomatology Systems Review score was considered a secondary outcome and showed a difference in outcome that was statistically significant in favor of VNS (17.4%) compared with sham treatment (7.5% p=0.04).

The observational study that compared patients participating in the RCT with patients in a separately recruited control group (D-04 vs D-02, respectively) evaluated VNS therapy out to 1 year and showed a statistically significant difference in the rate of change of depression score.\textsuperscript{42,44} However, issues such as unmeasured differences among patients, nonconcurrent controls, differences in sites of care between VNS therapy patients and controls, and differences in concomitant therapy change raise concern about this observational study. Analyses performed on subsets of patients cared for in the same sites, and censoring observations after treatment changes, generally showed diminished differences in apparent treatment effectiveness of VNS and almost no statistically significant differences.\textsuperscript{44} Patient selection for the randomized trial and the observational comparison trial may be of concern. VNS is intended for treatment-refractory depression, but the entry criteria of failure of 2 drugs and a 6-week trial of therapy might not be a strict enough definition of treatment resistance. Treatment-refractory depression should be defined by thorough psychiatric evaluation and comprehensive management. It is important to note that patients with clinically significant suicide risk were excluded from all VNS studies. Given these concerns about the quality of the observational data, these results did not provide strong evidence for the effectiveness of VNS therapy.

In addition to the results of the TEC Assessments, several systematic reviews and meta-analyses have assessed the role of VNS in treatment-resistant depression. A 2008 systematic review of the literature for VNS of treatment-resistant depression identified the randomized trial previously described among the 18 studies that met the study’s inclusion criteria.\textsuperscript{48} VNS was found to be associated with a reduction in depressive symptoms in the open-label studies. However, results from the only double-blind trial were considered inconclusive.\textsuperscript{43,44} Daban et al (2008) concluded that further clinical trials are needed to confirm efficacy of VNS in treatment-resistant depression.\textsuperscript{48}

In a meta-analysis that included 14 studies, Martin and Martin-Sanchez (2012) reported that, among the uncontrolled studies included in their analysis, 31.8% of subjects responded to VNS treatment.\textsuperscript{49} However, results from a meta-regression to predict each study’s effect size suggested that 84% of the observed variation across studies was explained by baseline depression severity. Berry et al (2013)\textsuperscript{50} reported on results from a meta-analysis of 6 industry-sponsored studies of safety and efficacy for VNS in treatment-resistant depression, which included the D-01, D-02, D-03 (Bajbouj et al [2010]\textsuperscript{51}), D-04, and D-21 (Aaronson et al [2013]\textsuperscript{52}) study results. Also, the meta-analysis used data from a registry of patients with treatment-resistant depression (335 patients receiving VNS plus treatment as usual and 301 patients receiving treatment as usual only) that were unpublished at the time of the meta-analysis publication (NCT00320372). The authors reported that adjunctive VNS was associated with a greater likelihood of treatment response (odds ratio, 3.19; 95% CI, 2.12 to 4.66). However, the meta-analysis did not have systematic study selection criteria, limiting the conclusions that can be drawn from it.

Liu et al (2014) conducted a systematic review of brain stimulation treatments, including deep brain stimulation, electroconvulsive therapy, transcranial magnetic stimulation, and VNS, for mental illnesses other than nonpsychotic unipolar depression in adults ages 65 years or older.\textsuperscript{53} Reviewers identified 2 small studies that evaluated the effect of VNS on cognition in patients with Alzheimer disease, one with 10 subjects and the other with 17 subjects, which were mixed in demonstrating clinical improvements.
Aaronson et al (2013) reported on results from an active-controlled trial in which 331 patients with a history of chronic or recurrent bipolar disorder or major depressive disorder, with a current diagnosis of a major depressive episode, were randomized to 1 of 3 VNS current doses (high, medium, low). Patients had a history of failure to respond to at least 4 adequate dose/duration of antidepressant treatment trials from at least 2 different treatment categories. After 22 weeks, the current dose could be adjusted in any of the groups. At follow-up visits at weeks 10, 14, 18, and 22 after enrollment, there were no statistically significant differences between the dose groups for the study’s primary outcome, change in IDS score from baseline. However, mean IDS scores improved significantly for each group from baseline to the 22-week follow-up. At 50-week follow-up, there were no significant differences between the treatment dose groups for any of the depression scores used. Most patients completed the study; however, there was a high rate of reported adverse events, including voice alteration in 72.2%, dyspnea in 32.3%, and pain in 31.7%. Interpretation of the IDS improvement over time is limited by the lack of a no-treatment control group. Approximately 20% of the patients included had a history of bipolar disorder; as such, the results might not be representative of most patients with treatment-resistant unipolar depression.

Other case series do not substantially strengthen the evidence supporting VNS. A case series by Bajbouj et al (2010), which followed patients for 2 years, showed that 53.1% (26/49) met criteria for a treatment response and 38.9% (19/49) met criteria for remission. A small 2008 study of 9 patients with rapid-cycling bipolar disorder showed improvements in several depression rating scales over 40 weeks of observation. Another case series, by Cristancho et al (2011), which followed patients for 1 year, showed that 4 of 15 responded and 1 of 15 remitted according to the principal response criteria. In a 2014 case series that included 27 patients with treatment-resistant depression, 5 patients demonstrated complete remission after 1 year, and 6 patients were considered responders.

Adverse events of VNS therapy included voice alteration, headache, neck pain, and cough, which are known from prior experience with VNS therapy for seizures. Regarding specific concerns for depressed patients (e.g., those with mania, hypomania, suicide, or worsening depression), there does not appear to be a greater risk of these events during VNS therapy.

**Section Summary: Treatment-Resistant Depression**
There is an RCT evaluating the efficacy of VNS for treatment-resistant depression. This trial reported only short-term results and found no significant improvement in the primary outcome with VNS. Other available studies, which include nonrandomized comparative studies and case series, are limited by relatively small sample sizes and the potential for selection bias; the case series are further limited by the lack of control groups. Given the limitations of this literature, combined with the lack of substantial new clinical trials, the scientific evidence is considered to be insufficient to permit conclusions on the effect of this technology on major depression. Another neuromodulation technique (transcranial magnetic stimulation) for the treatment of depression is evaluated in Blue Shield of California Medical Policy: Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders.

**Other Conditions**

**Treatment of Chronic Heart Failure**
VNS has been investigated for the treatment of chronic heart failure in case series. A 2011 phase 2 case series of VNS therapy for chronic heart failure reported improvements in New York Heart Association class quality of life, 6-minute walk test, and left ventricular (LV) ejection fraction. The ANTHEM-HF trial (2014) is another case series, but in it, patients were randomized to right- or left-sided vagus nerve implantation (but without a control group). Overall, from baseline to 6-month follow-up, a number of measures were improved: LV ejection fraction improved by 4.5% (95% CI, 2.4% to 6.6%); LV end-systolic volume improved by -4.1 mL (95% CI, -9.0 to 0.8 mL); LV end-diastolic diameter improved by -1.7 mm (95% CI, -2.8 to -0.7 mm); heart rate variability improved by 17 ms (95% CI, 6.5 to 28 ms); and 6-minute walk distance improved by 56 meters (95% CI, 37 to 75 meters).
Zannad et al (2015) reported on results from NECTAR-HF, a randomized, sham-controlled trial, with outcomes from VNS in patients with severe LV dysfunction despite optimal medical therapy. Ninety-six patients were implanted with a vagal nerve stimulator and randomized in a 2:1 manner to active therapy (VNS ON) or control (VNS OFF) for 6 months. Programming of the generator was performed by a physician unblinded to treatment assignment, while all other investigators and site study staff involved in the end point data collection were blinded to randomization. Sixty-three patients were randomized to the intervention, of whom 59 had paired pre-post data available, while 32 were randomized to control, of whom 28 had paired data available. The analysis was a modified intention-to-treat. For the primary end point of change in LV end-diastolic diameter from baseline to 6 months, there were no significant differences between groups (p=0.60 between-group difference in LV end-diastolic diameter change). Other secondary efficacy end points related to LV remodeling parameters (i.e., LV function and circulating biomarkers of heart failure) did not differ between groups, with the exception of 36-Item Short-Form Health Survey Physical Component Summary score, which showed greater improvement in the VNS ON group than in the control group (from 36.3 to 41.2 in the VNS ON group vs from 37.7 to 38.4 in the control group; p=0.02). Subject blinding was found to be imperfect, which might have biased the subjective outcome data reporting.

Treatment of Upper-Limb Impairment due to Stroke
Dawson et al (2016) conducted a randomized pilot trial of VNS in patients with upper-limb dysfunction after ischemic stroke. Twenty-one subjects were randomized to VNS plus rehabilitation or rehabilitation alone. The mean change in the outcome as assessed by a functional assessment score was +8.7 in the VNS group and +3.0 in the control group (p=0.064). Six patients in the VNS group achieved a clinically meaningful response and 4 in the control group (p=0.17).

Essential Tremor, Headache, Fibromyalgia, Tinnitus, and Autism
VNS has been investigated with small pilot studies or studies evaluating the mechanism of disease for several conditions. These conditions include essential tremor, fibromyalgia, headaches, and tinnitus. The utility of VNS added to behavioral management of autism and autism spectrum disorders has been posted, but there are no RCTs. None of these studies are sufficient to draw conclusions on the effect of VNS on these conditions.

Section Summary: Other Conditions
In other conditions evaluated with RCTs (heart failure, upper-limb impairment), the trials failed to show the efficacy of VNS for the primary outcome. Other conditions (essential tremor, headache, fibromyalgia, tinnitus, autism) have only been investigated with case series, which are not sufficient to draw conclusions on the effect of VNS.

Transcutaneous Vagus Nerve Stimulation
Only conditions for which there is at least 1 RCT assessing the use of transcutaneous VNS (t-VNS) are discussed because case series are inadequate to determine the effect of the technology.

Episodic Cluster Headaches
Goadsby et al (2017) reported on the results of randomized, double-blind, sham-controlled study (ACT2) for the treatment of cluster headache attacks. Ninety-two patients with cluster headaches were randomized to t-VNS (described in this response as noninvasive VNS) or sham treatment. Patients were further identified as having episodic cluster headaches or chronic cluster headaches and randomized at approximately 1:1 to the t-VNS and sham treatment groups. The primary efficacy end point was the ability to achieve pain-free status within 15 minutes of initiation of treatment without use of rescue treatment. There was no difference between t-VNS-treated and sham-treated patients in the overall cluster headache study population. Subgroup analysis of the chronic cluster headache population showed no differences between t-VNS-treated and sham-treated patients. For the episodic cluster...
headaches subgroup, t-VNS demonstrated a 48% response rate compared with 6% response rate for sham-treated (p < 0.01).

Silberstein et al (2016) reported on the results of a randomized, double-blind, sham-controlled study (ACT1) of cluster headache attacks.68 One hundred fifty patients with cluster headaches were randomized to t-VNS or sham treatment. Patients were further identified as having episodic cluster headaches or chronic cluster headaches and randomized at approximately 1:1 to the t-VNS and sham treatment groups. The primary end point was response rate defined as the ability to achieve pain-free status within 15 minutes of initiation of treatment without rescue medication use through 60 minutes. There were no differences between t-VNS-treated and sham-treated patients in the overall cluster headache study population. Subgroup analysis of the chronic cluster headache population showed no differences between t-VNS-treated and sham-treated patients. For the episodic cluster headache subgroup, t-VNS demonstrated a 34.2% response rate compared with 10.6% response rate for sham-treated (p = 0.008).

Gaul et al (2016) reported on the results of a randomized open-label study of t-VNS for the treatment of chronic cluster headache.69 Forty-eight patients with chronic cluster headache were randomized to t-VNS or individualized standard of care. Transcutaneous VNS was to be used twice daily with the option of additional treatment during headaches. At 4 weeks, the t-VNS group had a greater reduction in the number of headaches than the control group, resulting in a mean therapeutic gain of 3.9 fewer headaches per week (p = 0.02). Regarding response rate, defined as a 50% or more reduction in headaches, the t-VNS group had a 40% response rate, and the control group had an 8.3% response rate (p < 0.001). The study lacked a sham placebo control group, which might have resulted in placebo response in the t-VNS group.

Subsection Summary: Transcutaneous Vagus Nerve Stimulation for Episodic Cluster Headaches
Transcutaneous (or noninvasive) VNS has been investigated for episodic cluster headaches in 3 RCTs. One RCT assessing cluster headache showed a reduction in headache frequency but did not have a sham treatment group. Two randomized, double-blind, sham-controlled studies (ACT1 and ACT2) showed efficacy in achieving pain-free status within 15 minutes of treatment with t-VNS. However, the ACT1 and ACT2 studies had small episodic cluster headache subgroups of 85 (38 treated, 45 sham) and 27 (14 treated, 13 sham) respectively. Additional studies with larger cohorts of patients with episodic cluster headache are required given the small sample sizes evaluated in these trials.

Other Neurologic, Psychiatric, or Metabolic Disorders
Epilepsy
Aihua et al (2014) reported on results from a series of 60 patients with pharmaco-resistant epilepsy treated with a t-VNS device, who were randomized to stimulation over the earlobe (control group) or the Ramsay-Hunt zone (treatment group), which includes the external auditory canal and the conchal cavity and is considered to be the somatic sensory territory of the vagus nerve.70 Thirty patients were randomized to each group; 4 subjects from the treatment group were excluded from analysis due to loss to follow-up (n=3) or adverse events (n=1), while 9 subjects from the control group were excluded from analysis due to loss to follow-up (n=2) or increase or lack of decrease in seizures or other reasons (n=7). In the treatment group, compared with baseline, the median monthly seizure frequency was significantly reduced after 6 months (5.5 months vs 6.0 months; p < 0.001) and 12 months (4.0 months vs 6.0 months; p < 0.001) of t-VNS therapy. At 12-month follow-up, t-VNS group subjects had a significantly lower median monthly seizure frequency compared with the control group (4.0 months vs 8.0 months; p < 0.001).

Two small case series identified used a t-VNS device for treatment of medication-refractory seizures. In a small case series of 10 patients with treatment-resistant epilepsy, Stefan et al (2012) reported that 3 patients withdrew from the study, while 5 of 7 patients reported a reduction in seizure frequency.71 In another small case series, He et al (2013) reported that, among 14 pediatric patients with intractable epilepsy who were treated with bilateral t-VNS, of the 13
patients who completed follow-up, the mean reduction in self-reported seizure frequency was 31.8% after 8 weeks, 54.1% from week 9 to 16, and 54.2% from week 17 to 24.\textsuperscript{72}

### Psychiatric Disorders

Hein et al (2013) reported on results of 2 pilot RCTs of a t-VNS device for the treatment of depression, one of which included 22 subjects and another assessed 15 subjects.\textsuperscript{73} In the first study, 11 subjects were randomized to active or sham t-VNS. At 2-week follow-up, Beck Depression Inventory (BDI) self-rating scores in the active stimulation group decreased from 27.0 to 14.0 points (\(p<0.001\)), while the sham-stimulated patients did not show significant reductions in BDI scores (31.0 to 25.8 points). In the second study, 7 patients were randomized to active t-VNS, and 8 patients were randomized to sham t-VNS. In this study, BDI self-rating scores in the active stimulation group decreased from 29.4 to 17.4 points (\(p<0.05\)) after 2 weeks, while the sham-stimulated patients did not show a significant change in BDI scores (28.6 to 25.4 points). The authors did not report direct comparisons in BDI change scores between the sham- and active-stimulation groups.

Hasan et al (2015) reported on a randomized trial of t-VNS for the treatment of schizophrenia.\textsuperscript{74} Twenty patients were assigned to active t-VNS or sham treatment for 12 weeks. There was no statistically significant difference in the improvement of schizophrenia status during the observation period.

Shiozawa et al (2014) conducted a systematic review of studies evaluating the evidence related to transcutaneous stimulation of the trigeminal or vagus nerve for psychiatric disorders.\textsuperscript{75} They found 4 studies addressing t-VNS for psychiatric disorders (total N=84 subjects). Three of the 4 studies evaluated physiologic parameters in healthy patients, and one evaluated pharmacoresistant epilepsy (Stefan et al [2012];\textsuperscript{71} previously described). Reviewers also included a fifth study in a data table, although not in their text or a reference list (Hein et al [2013];\textsuperscript{73} previously described). Overall, the studies assessed were limited by small size and poor generalizability.

### Other Headaches

Goadsby et al (2014) reported on results from an open-label pilot study of t-VNS for the treatment of a migraine with or without aura.\textsuperscript{76} Eighty migraine attacks were self-treated by 27 patients, of an initial sample of 30 patients (2 patients treated no migraine attacks with the device, 1 patient treated only an aura). Of 54 moderate or severe attacks treated, 12 subjects (22%) were pain-free at 2 hours posttreatment. Thirteen subjects reported adverse events, which were all considered mild or moderate.

Tso et al (2017) evaluated the records of 15 patients treated with a t-VNS device (gammaCore) for paroxysmal hemicrania (n=6) or hemicrania continua (n=9) as primary treatment or as an adjunct to indomethacin.\textsuperscript{77} Symptom-related outcomes included reduction of pain severity and reduced frequency of attacks; for the first, 7 hemicrania continua patients saw improvement with t-VNS therapy, as did 3 patients with paroxysmal hemicranias. The frequency of attacks was reduced for 2 hemicrania continua patients and 2 paroxysmal hemicranias patients. Some adverse events were reported in all patients, although not detailed.

### Impaired Glucose Tolerance

Huang et al (2014) reported on results of a pilot RCT of a t-VNS device that provides stimulation to the auricle for the treatment of impaired glucose tolerance.\textsuperscript{78} The trial included 70 patients with impaired glucose tolerance who were randomized to active or sham t-VNS, along with 30 controls who received no t-VNS treatment. After 12 weeks of treatment, patients who received active t-VNS were reported to have significantly lower 2-hour glucose tolerance test results than those who received sham t-VNS (7.5 mmol/L vs 8 mmol/L; \(p=0.004\)).

### Section Summary: Transcutaneous VNS for Other Neurologic, Psychiatric, or Metabolic Disorders

Transcutaneous VNS has been investigated in small randomized trials for several conditions. Some evidence for the efficacy of t-VNS for epilepsy comes from a small RCT, which reported
lower seizure rates for active t-VNS-treated patients than for sham controls; however, the high dropout rates in this trial are problematic. In the study of depression, a small RCT that compared treatment using t-VNS with sham stimulation demonstrated some improvements in depression scores with t-VNS; however, the lack of comparisons between groups limits conclusions that might be drawn. A sham-controlled pilot randomized trial for impaired glucose tolerance showed some effect on glucose tolerance tests.

Summary of Evidence

Vagus Nerve Stimulation

For individuals who have seizures refractory to medical treatment who receive VNS, the evidence includes RCTs and multiple observational studies. Relevant outcomes are symptoms, change in disease status, and functional outcomes. The RCTs have reported significant reductions in seizure frequency for patients with partial-onset seizures. The uncontrolled studies have consistently reported large reductions in a broader range of seizure types in both adults and children. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have treatment-resistant depression who receive VNS, the evidence includes an RCT, nonrandomized comparative studies, and case series. Relevant outcomes are symptoms, change in disease status, and functional outcomes. The RCT only reported short-term results and found no significant improvement in the primary outcome. Other available studies are limited by small sample sizes, potential selection bias, and lack of a control group in the case series. The evidence is insufficient to determine the effects of the technology on health outcomes.

Other Conditions

For individuals who have chronic heart failure who receive VNS, the evidence includes RCTs and case series. Relevant outcomes are symptoms, change in disease status, and functional outcomes. The RCTs evaluating chronic heart failure did not show significant improvements in the primary outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have upper-limb impairment due to stroke who receive VNS, the evidence includes a single pilot study. Relevant outcomes are symptoms, change in disease status, and functional outcomes. This pilot study has provided preliminary support for improvement in functional outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have other neurologic conditions (e.g., essential tremor, headache, fibromyalgia, tinnitus, autism) who receive VNS, the evidence includes case series. Relevant outcomes are symptoms, change in disease status, and functional outcomes. Case series are insufficient to draw conclusions regarding efficacy. The evidence is insufficient to determine the effects of the technology on health outcomes.

Transcutaneous Vagus Nerve Stimulation

For individuals with episodic cluster headaches who receive transcutaneous VNS, the evidence includes 3 RCTs. One RCT for cluster headache showed a reduction in headache frequency but did not include a sham treatment group. Two randomized, double-blind, sham-controlled studies showed efficacy of achieving pain-free status within 15 minutes of treatment with noninvasive VNS in patients with episodic cluster headaches but not in patients with chronic cluster headaches. The RCTs for episodic cluster headaches are promising, however, additional studies with larger relevant populations are required to establish the treatment efficacy. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have other neurologic, psychiatric, or metabolic disorders (e.g., epilepsy, depression, schizophrenia, noncluster headache, impaired glucose tolerance) who receive
transcutaneous VNS, the evidence includes RCTs and case series for some of the conditions. Relevant outcomes are symptoms, change in disease status, and functional outcomes. The RCTs are all small and have various methodologic problems. None showed definitive efficacy of transcutaneous VNS in improving patient outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Supplemental Information**

**Practice Guidelines and Position Statements**

**American Academy of Neurology**

In 1999, the American Academy of Neurology released a consensus statement on the use of vagus nerve stimulation (VNS) in adults, which stated: “VNS is indicated for adults and adolescents over 12 years of age with medically intractable partial seizures who are not candidates for potentially curative surgical resections, such as lesionectomies or mesial temporal lobectomies.”

The Academy updated these guidelines in 2013, stating: “VNS may be considered for seizures in children, for LGS [Lennox-Gastaut syndrome]-associated seizures, and for improving mood in adults with epilepsy (Level C). VNS may be considered to have improved efficacy over time (Level C).”

An update is reported to be in progress at the time of this review update.

**American Psychiatric Association**

The American Psychiatric Association guidelines for the treatment of major depressive disorder in adults, updated in 2010, included the following statement on the use of VNS: “Vagus nerve stimulation (VNS) may be an additional option for individuals who have not responded to at least four adequate trials of antidepressant treatment, including ECT [electroconvulsive therapy],” with a level of evidence III (may be recommended on the basis of individual circumstances).

**European Headache Federation**

In 2013, the European Headache Federation issued a consensus statement on neuromodulation treatments for chronic headaches, which made the following statement about the use of VNS: “Due to the lack of evidence, VNS should only be employed in chronic headache sufferers using a randomized, placebo controlled trial design.”

**U.S. Preventive Services Task Force Recommendations**

Not applicable.

**Medicare National Coverage**

Medicare has a national coverage determination for VNS. Medicare coverage policy notes that “Clinical evidence has shown that vagus nerve stimulation is safe and effective treatment for patients with medically refractory partial onset seizures, for whom surgery is not recommended or for whom surgery has failed. Vagus nerve stimulation is not covered for patients with other types of seizure disorders that are medically refractory and for whom surgery is not recommended or for whom surgery has failed.” Effective May 2007, VNS is not reasonable and necessary for resistant depression.

**Ongoing and Unpublished Clinical Trials**

Some currently unpublished trials that might influence this review are listed in Table 5.

**Table 5. Summary of Key Trials**

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02113033a</td>
<td>Vagal Nerve Stimulation: safeGUARDing Heart Failure Patients</td>
<td>20</td>
<td>Mar 2016 (ongoing)</td>
</tr>
<tr>
<td>NCT02385526a</td>
<td>ASCEND: Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation</td>
<td>60</td>
<td>Apr 2017 (ongoing)</td>
</tr>
<tr>
<td>NCT No.</td>
<td>Trial Name</td>
<td>Planned Enrollment</td>
<td>Completion Date</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>NCT02686034a</td>
<td>A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled Study of gammaCore® Non-invasive Vagus Nerve Stimulator (nVNS), for the Acute Treatment of Migraine</td>
<td>300</td>
<td>Apr 2017 (ongoing)</td>
</tr>
<tr>
<td>NCT02378792a</td>
<td>The Clinical Research on TsingHua Vagus Nerve Stimulator for Treatment of Refractory Epilepsy Enrollment</td>
<td>300</td>
<td>Dec 2017 (ongoing)</td>
</tr>
<tr>
<td>NCT02983448</td>
<td>Noninvasive Neuromodulation to Reserve Diastolic Dysfunction</td>
<td>26</td>
<td>Dec 2017 (ongoing)</td>
</tr>
<tr>
<td>NCT03062514a</td>
<td>Vagus Nerve Stimulation for Pediatric Intractable Epilepsy (VNS-PIE)</td>
<td>84</td>
<td>Mar 2018</td>
</tr>
<tr>
<td>NCT02648191</td>
<td>Preoperative Treatment With Noninvasive Intra-auricular Vagus Nerve Stimulation Pending Bariatric Surgery. A Randomized, Controlled, Double-blind Trial</td>
<td>50</td>
<td>Apr 2018</td>
</tr>
<tr>
<td>NCT03380156</td>
<td>Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function and Arterial Stiffness in Patients With Heart Failure With Reduced Ejection Fraction</td>
<td>25</td>
<td>May 2018</td>
</tr>
<tr>
<td>NCT02359188</td>
<td>Influence of Transcutaneous Vagal Nerve Stimulation on Expression of microRNA, Cytokines, Chemokines and Neuropeptides as Well as Cerebral Resting State and Gastric Motility</td>
<td>60</td>
<td>Aug 2018</td>
</tr>
<tr>
<td>NCT01281293a</td>
<td>A Post Market, Long Term, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy</td>
<td>124</td>
<td>Dec 2018</td>
</tr>
<tr>
<td>NCT03163030a</td>
<td>Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure With Preserved Ejection Fraction (ANTHEM-HFpEF) Study</td>
<td>50</td>
<td>Dec 2018</td>
</tr>
<tr>
<td>NCT03217929</td>
<td>Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Food Craving in Obese Individuals: A Randomized, Sham-controlled, Double Blind Clinical Trial</td>
<td>54</td>
<td>Oct 2019</td>
</tr>
<tr>
<td>NCT03282110</td>
<td>Comprehensive Acupuncture for Depressive Disorder With Comorbid Psychogenic Pain: Randomized Controlled Study</td>
<td>60</td>
<td>Jun 2019</td>
</tr>
<tr>
<td>NCT03327649</td>
<td>Neuromodulation of Inflammation to Treat Heart Failure With Preserved Ejection Fraction</td>
<td>72</td>
<td>Dec 2019</td>
</tr>
<tr>
<td>NCT03320304a</td>
<td>A Global Prospective, Multi-enter, Observational Post-market Study To Assess Short, Mid and Long-term Effectiveness and Efficiency of VNS Therapy® as Adjunctive Therapy in Real-world Patients With Difficult to Treat Depression</td>
<td>500</td>
<td>Dec 2025</td>
</tr>
<tr>
<td>Unpublished</td>
<td>Transcutaneous Vagus Nerve Stimulation for Treating Major Depressive Disorder: a Phase II, Randomized, Double-blind Clinical Trial</td>
<td>40</td>
<td>Jul 2016 (unknown)</td>
</tr>
<tr>
<td>NCT02089243</td>
<td>Prospective Randomized Controlled Study of Vagus Nerve Stimulation Therapy in the Patients With Medically Refractory Medial Temporal Lobe Epilepsy; Controlled Randomized Vagus Nerve Stimulation Versus Resection (CoRaVNSriR)</td>
<td>40</td>
<td>Jul 2017 (unknown)</td>
</tr>
<tr>
<td>NCT01958125a</td>
<td>A Randomized, Multi-centre, Double-blind, Parallel, Sham-controlled Study of GammaCore®, a Non-invasive Neurostimulator Device for the Acute Relief of Episodic and Chronic Cluster Headache</td>
<td>120</td>
<td>Jan 2015 (completed)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
a Denotes industry-sponsored or cosponsored trial.

References


### Documentation for Clinical Review

**Please provide the following documentation (if/when requested):**

- **History and physical and/or consultation notes including:**
  - Reason for vagus nerve stimulation
  - Type of device used

**Post Service**

- Operative report(s)

### Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

**MN/IE**

The following services may be considered medically necessary in certain instances and investigational in others. Services may be considered medically necessary when policy criteria are met. Services may be considered investigational when the policy criteria are not met or when the code describes application of a product in the position statement that is investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT®</td>
<td>61885</td>
<td>Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array</td>
</tr>
<tr>
<td></td>
<td>61886</td>
<td>Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays</td>
</tr>
<tr>
<td>Type</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>--------</td>
<td>---------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>61888</td>
<td>Revision or removal of cranial neurostimulator pulse generator or receiver</td>
</tr>
<tr>
<td></td>
<td>64553</td>
<td>Percutaneous implantation of neurostimulator electrode array; cranial nerve</td>
</tr>
<tr>
<td></td>
<td>64568</td>
<td>Incision for implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator</td>
</tr>
<tr>
<td></td>
<td>64569</td>
<td>Revision or replacement of cranial nerve (e.g., vagus nerve) neurostimulator electrode array, including connection to existing pulse generator</td>
</tr>
<tr>
<td></td>
<td>64570</td>
<td>Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator</td>
</tr>
<tr>
<td></td>
<td>95974</td>
<td>Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour</td>
</tr>
<tr>
<td></td>
<td>95975</td>
<td>Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>HCPCS</td>
<td>C1767</td>
<td>Generator, neurostimulator (implantable), nonrechargeable</td>
</tr>
<tr>
<td></td>
<td>L8680</td>
<td>Implantable neurostimulator electrode, each</td>
</tr>
<tr>
<td></td>
<td>L8681</td>
<td>Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only</td>
</tr>
<tr>
<td></td>
<td>L8682</td>
<td>Implantable neurostimulator radiofrequency receiver</td>
</tr>
<tr>
<td></td>
<td>L8683</td>
<td>Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver</td>
</tr>
<tr>
<td></td>
<td>L8685</td>
<td>Implantable neurostimulator pulse generator, single array, rechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8686</td>
<td>Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8687</td>
<td>Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8688</td>
<td>Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8689</td>
<td>External recharging system for battery (internal) for use with implantable neurostimulator, replacement only</td>
</tr>
<tr>
<td></td>
<td>L8695</td>
<td>External recharging system for battery (external) for use with implantable neurostimulator, replacement only</td>
</tr>
<tr>
<td>ICD-10</td>
<td>00HE0MZ</td>
<td>Insertion of Neurostimulator Lead into Cranial Nerve, Open Approach</td>
</tr>
<tr>
<td>Procedure</td>
<td>00HE3MZ</td>
<td>Insertion of Neurostimulator Lead into Cranial Nerve, Percutaneous Approach</td>
</tr>
<tr>
<td></td>
<td>00HE4MZ</td>
<td>Insertion of Neurostimulator Lead into Cranial Nerve, Percutaneous Endoscopic Approach</td>
</tr>
<tr>
<td></td>
<td>00PE0MZ</td>
<td>Removal of Neurostimulator Lead from Cranial Nerve, Open Approach</td>
</tr>
</tbody>
</table>
Type | Code | Description |
--- | --- | ---|
| Removal of Neurostimulator Lead from Cranial Nerve, Percutaneous Approach |
| Removal of Neurostimulator Lead from Cranial Nerve, Percutaneous Endoscopic Approach |
| Insertion of Single Array Stimulator Generator into Chest Subcutaneous Tissue and Fascia, Open Approach |
| Insertion of Single Array Rechargeable Stimulator Generator into Chest Subcutaneous Tissue and Fascia, Open Approach |
| Insertion of Multiple Array Stimulator Generator into Chest Subcutaneous Tissue and Fascia, Open Approach |
| Insertion of Multiple Array Rechargeable Stimulator Generator into Chest Subcutaneous Tissue and Fascia, Open Approach |
| Insertion of Single Array Stimulator Generator into Chest Subcutaneous Tissue and Fascia, Percutaneous Approach |
| Insertion of Single Array Rechargeable Stimulator Generator into Chest Subcutaneous Tissue and Fascia, Percutaneous Approach |
| Insertion of Multiple Array Stimulator Generator into Chest Subcutaneous Tissue and Fascia, Percutaneous Approach |
| Insertion of Multiple Array Rechargeable Stimulator Generator into Chest Subcutaneous Tissue and Fascia, Percutaneous Approach |
| Insertion of Single Array Stimulator Generator into Abdomen Subcutaneous Tissue and Fascia, Open Approach |
| Insertion of Single Array Rechargeable Stimulator Generator into Abdomen Subcutaneous Tissue and Fascia, Open Approach |
| Insertion of Multiple Array Stimulator Generator into Abdomen Subcutaneous Tissue and Fascia, Open Approach |
| Insertion of Multiple Array Rechargeable Stimulator Generator into Abdomen Subcutaneous Tissue and Fascia, Open Approach |
| Insertion of Single Array Stimulator Generator into Abdomen Subcutaneous Tissue and Fascia, Percutaneous Approach |
| Insertion of Single Array Rechargeable Stimulator Generator into Abdomen Subcutaneous Tissue and Fascia, Percutaneous Approach |
| Insertion of Multiple Array Stimulator Generator into Abdomen Subcutaneous Tissue and Fascia, Percutaneous Approach |
| Insertion of Multiple Array Rechargeable Stimulator Generator into Abdomen Subcutaneous Tissue and Fascia, Percutaneous Approach |
| Removal of Stimulator Generator from Trunk Subcutaneous Tissue and Fascia, Open Approach |
| Removal of Stimulator Generator from Trunk Subcutaneous Tissue and Fascia, Percutaneous Approach |

**Policy History**

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/01/2005</td>
<td>Medical Policy Committee accepted CTAF as consent BCBSA TEC review Vol.20 No.8. New Policy</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>03/01/2006</td>
<td>MPC accepted CTAF February technology review: VNS. Policy updated; Policy statement unchanged.</td>
<td>Medical Policy Committee</td>
</tr>
</tbody>
</table>
### Definitions of Decision Determinations

**Medically Necessary:** A treatment, procedure, or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

### Prior Authorization Requirements (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department. Please call (800) 541-6652 or visit the provider portal at www.blueshieldca.com/provider.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.